Tag Archives: Continue

NLS Pharmaceutics Appoints Silvia Panigone, Ph.D. As Chief Operating Officer | Instant News


STANS, Switzerland, April 5, 2021 / PRNewswire / – NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) (“NLS” or “Company”), a Swiss clinical stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare central diseases and complex nervous system disorders, announced the appointment of Silvia Panigone, Ph. .D., EMBA as Chief Operating Officer. Dr. Panigone brings to NLS more than 25 years of leadership experience in the health care industry, founded and operates ADYA Consulting, a boutique advisory firm that provides strategic counseling, access to capital, and M&A consulting services to companies in the life science sector, and serves in operational and managerials in international pharmaceutical companies and clinical research organizations.

“Silvia’s outstanding experience in product development and strategic leadership in the life science industry is a perfect fit for NLS as we pursue development of Quilience® to treat narcolepsy, and define our strategy for business development and advancement of our drug pathway,” said Alex Zwyer, Executive Director of NLS Pharmaceutics. “Its proven ability to guide emerging biotech and pharmaceutical companies from the early stages of development through a period of significant growth will be critical as we seek to drive corporate initiatives and build value within the Company. All of us at NLS give a warm welcome to Silvia. “

“I am delighted to join the NLS team and oversee the main operational activities of the Company so that we can provide patients with new treatments for rare and complex CNS disorders,” said Dr. Panigone. “NLS is focused on developing therapies intended to meet unmet medical needs, and our flagship product, Quilience, ® has the potential to be the first-line treatment for narcolepsy targeting the orexin-2 receptor, the root cause of the disorder. Given the importance of this candidate product, a top priority we are getting IND approval in the US and getting Quilience to the clinic as fast as possible. “

Prior to joining the NLS, Dr. Panigone is the managing director of ADYA Consulting Sagl, a Swiss investment boutique in the life science sector that operates globally and supports companies in corporate strategy and fundraising. He has also acted as temporary management in about one-third of ADYA’s biotech and pharmaceutical clients, and has held several Board positions in private companies, helping some to realize M&A solutions. Dr. Panigone combines a deep understanding of corporate finance as well as the drug development process and execution. Prior to ADYA, he was the former President Director Europe at I-Bankers Direct LLC, an equity funding web platform, as well as Advisor to I-Bankers Securities, Inc., a US investment banking group with more than 140 main offerings and co-managed offerings. He previously served as Fund Manager at BSI Healthcapital, a life science-focused venture capital firm, and Head of Venture Investments in the Merchant division of the Swiss-based bank, EFG International. Dr. R&D Experience Panigone’s broad range includes serving in operational and managerial positions at international level in pharmaceutical and CRO companies. At Bracco SpA, he leads international programs at both the preclinical and clinical stages with the regulatory team, intellectual property, CMC, preclinical and clinical internal experts, external providers, and KOL overseeing the development program as a Sponsor. He is also Global Project Manager at Quintiles Innovex Ltd., a leading global CRO, where he is responsible for managing a large clinical program conducted in the USA, Europe and Asia. Previously, Dr. Panigone serves as Senior Director at XoVenture, a global network of Life Science entrepreneurs and executives, Start-Up Coach for the Swiss government (Innosuisse), University Board Member Milan, and is a member of the European Narcolepsy Network (EUNN). He obtained a degree in Molecular Biology from the University of Milan, Ph.D. in Molecular Oncology at the National Cancer Institute and the Open University, London, and the Executive MBA from the Bocconi SDA School of Management, Milan.

Aabout NLS Pharmaceutics Ltd.

NLS Pharmaceutics Ltd. is a Swiss-based clinical stage biopharmaceutical company led by an experienced management team with a track record of developing and reusing candidate products to treat rare and complex central nervous system disorders. The Company’s main product candidate, Quilience® is a controlled release formulation of mazindol (mazindol CR) (mazindol CR), and is being developed for the treatment of narcolepsy. Mazindol is a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, which has been used for many years to treat patients diagnosed with narcolepsy in a compassionate use program. The NLS completed a phase 2 study in the US evaluating mazindol CR in adult subjects with ADHD. This study met all primary and secondary end points and was well tolerated. Quilience has received the Orphan Drug Designation both in the US and in Europe for the treatment of narcolepsy.

Safe Harbor Statement

This press release contains the express or implied forward-looking statements pursuant to US Federal securities laws. For example, the NLS uses forward-looking statements when discussing Quilience® which could potentially be the first treatment for narcolepsy targeting the orexin-2 receptor, the root cause of the disorder, as well as when discussing its strategy and pipeline. , initiatives and building values, and potential benefits and approvals from Quilience®. These forward-looking statements and their implications are based on the current expectations of NLS management only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; The NLS may experience delays or bottlenecks in its launch and / or successful completion of its clinical trials; NLS products may not be approved by regulatory bodies, NLS technology may not be validated due to further advances and its methods may not be accepted by the scientific community; NLS may not be able to retain or attract key employees whose knowledge is essential to product development; Unexpected scientific difficulties may develop with the NLS process; The NLS product may become more expensive than anticipated; laboratory results may not translate to equally good results in real clinical settings; the results of preclinical studies may not correlate with the results of clinical trials in humans; The NLS patent may not be enough; NLS products can harm recipients; a change in the law could have a devastating effect on the NLS; inability to develop and introduce new technologies, products and applications in a timely manner; loss of market share and pressure on prices due to competition, which could cause NLS’s actual results or performance to differ materially from those intended in those forward-looking statements. Unless required by law, NLS has no obligation to publish any revisions to this forward-looking statement to reflect events or circumstances after the date of this agreement or to reflect unforeseen events. More detailed information about the risks and uncertainties affecting NLS is provided under the heading “Risk Factors” in the final prospectus of NLS, dated January 28, 2021, filed with the SEC, which is available on the SEC website, www.sec.gov.

Company Contact
Alex Zwyer, CEO: +41 41 618 80 00

Investor Relations Contact
David Moscowitz: +1 202-280-0888

www.nlspharma.com

Cision View original content for multimedia downloads:http://www.prnewswire.com/news-releases/nls-pharmaceutics-appoints-silvia-panigone-phd-as-chief-operating-officer-301261618.html

SOURCE NLS Pharmaceutics Ltd.

.



image source

PPP will continue to guard the parliament, said Asif Zardari | Instant News


  1. | Bilawal postponed the party’s CEC meeting to discuss resigning from the assembly | Former President claims the PPP will defeat any conspiracy against the 18th Amendment | The Opposition’s failure cannot expose Imran Khan, I am the Chairman of the PPP

ISLAMABAD / KHAIRPUR – Pakistan People’s Party MP Asif Ali Zardari said on Saturday that the philosophy and ideology of Pakistan People’s Party founder Shaheed Zulfikar Ali Bhutto serves as a guide for us and the PPP will continue to maintain the parliamentary system in the country.

Earlier, Pakistan People’s Party Chairman Bilawal Bhutto Zardari postponed the party’s Central Executive Committee (CEC) meeting scheduled for April 5 due to Senate and National Assembly sessions.

Pakistan People’s Party (PPP) Secretary General Syed Nayyer Hussain Bukhari on Saturday said the decision was taken because most party members had to attend the upper and lower house assemblies of parliament and would not be able to attend the CEC meeting, said a statement issued here.

President Zardari said this in his message on the anniversary of Shaheed Zulfikar Ali Bhutto’s martyrdom. He said that the party would never compromise on the principle that the people are the source of power.

Quaid-e-Awam built this nation from the ashes of defeat and gave voice and courage to the oppressed masses to fight for their rights. He changed political trends and established the rules of the people. He showed the world that true leaders of the people accept death with grace but do not compromise on principles. “Today we reiterate our determination to continue to defend the country and its constitution,” he added.

The PPP gave the 1973 constitution and returned it to its original form with the 18th amendment and fulfilled the promise of provincial autonomy made by Quaid-e-Awam to the people, “he added. The PPP will defeat any conspiracy against the 18th amendment, he vows.

Addressing a press conference at the residence of former Chief Minister of Sindh Sayed Qaim Ali Shah in Khairpur, Bilawal Bhutto Zardari regretted that the PPP was the only political party opposing the ruling government and asked members of the opposition to put aside differences and unite. against the government.

Bilawal Bhutto Zardari said it was “good luck” from the government and Prime Minister Imran Khan that the opposition did not hold a motion of no confidence against him after the government’s defeat in the Islamabad Senate seat election.

“Our other Opposition friends have made opposition to the opposition (PPP),” said Bilawal. He said only Prime Minister Imran Khan benefited from the lack of unity among the opposition and the failure of the opposition which could not expose “Imran Khan’s attempts to seize the independence of the state bank and also failed to expose Imran Khan’s hypocrisy as far as Kashmir is concerned.

Bilawal reiterated the PPP’s desire for joint opposition with other political parties, which is why the foundation of the Pakistan Democratic Movement (PDM) was laid on September 20, 2020.

The PPP chairman said getting involved in accusations did not benefit any opposition party, which is why he refused to respond to any of them. “If not, you know we can come up with a one-size-fits-all answer.” The PPP has called a CEC meeting to decide on resigning from the assembly after its leadership came under criticism from Opposition parties over the matter. While all the major parties have shown their willingness to move, the PPP has found time to consider the matter. Bilawal said.

He hopes PDM Chairman Maulana Fazlur Rehman will recover soon because he has “a very important role to play as the leader of the PDM”. Bilawal also prayed for Fazl Rehman’s early recovery. Bilawal urged PML-N to show strength and a cold temperament.

“We were happy when PML-N won the by-election, so PML-N should also be happy with PPP’s success and we must not spoil the big goals we have gathered because of petty jealousies.”

He said the aim of the PDM was for democracy to develop, to ensure free and fair elections and the protection of the people.

Previously, Bilawal Bhutto Zardari visited the residence of former Chief Minister Sindh Sayed Qaim Ali Shah and MNA Sayed Nafisa Shah and expressed deep sorrow over the deaths of Muzaffar Ali Shah and Ms Najima Shah, son and daughter of Qaim Ali Shah, and prayed. Allah Almighty provides a great palace in heaven for the souls who have died.

Qamar Zaman Kaira, Sayed Nasir Shah, Sayed Owais Qadir Shah, provincial minister, Nisar Ahmed Khuhro, president of PPP Sindh province, provincial ministers including Suhail Anwar Siyal, Eijaz Jakhrani, Noman Islam Shaikh, Sayed Furukh Ahmed Shah, Irslan Islam Shaikh, Eijaz Dhamirah , Nawab Khan Wassan, Sajid Bhanbhan, Naeem Khurral, Munwar Wassan and others were also present on this occasion.

.



image source

ANGLE PLC Announces Global Launch of the Clinical Services Laboratory | Instant News


  • Delivered a strategy to accelerate the commercialization of the Parsortix system and act as a demonstrator to support product deployment
  • UK and US clinical laboratories are now open and ready to provide analysis services and ongoing CTC discussions with pharmaceutical industry customers

GUILDFORD, SURREY / ACCESS / 30 March 2021 / ANGLE plc (AIM: AGL) (OTCQX: ANPCY), the world’s leading fluid biopsy company, is pleased to announce that they have completed fitout and staffing at clinical services laboratories in Guildford UK, and Plymouth Meeting PA, USA. The launch was ahead of schedule with US laboratories completing earlier than anticipated and UK laboratories opening at the anticipated timeframe. Together, these laboratories will enable ANGLE to accelerate the commercial deployment of Parsortix® systems by offering services to pharmaceutical and biotechnological customers for use in clinical trials of cancer drugs and, once the laboratory is accredited and tests validated, through the provision of Laboratory Developed Tests (LDTs) for patient care.

ANGLE samples to answer the liquid biopsy solution via a simple blood test allow longitudinal monitoring of the patient during drug trials (before, during and after drug intervention) which is not possible with tissue biopsy. This is a significant market opportunity for ANGLE. In one segment of this market, there are more than 2,000 PD-L1 / PD-1 intervention trials registered on clinicaltrials.gov, enrolling more than 300,000 patients, who would be potential targets for ANGLE’s pharmaceutical services business.

ANGLE is targeting future clinical studies for the application of the Parsortix system and has developed service capabilities in the United Kingdom and the United States to process samples on a commercial scale as part of global pharmaceutical trials. ANGLE has established dialogues with potential customers and collaborators on the application of CTC liquid biopsy analysis in cancer drug trials, with these conversations at an advanced stage.

Both UK and US laboratories will seek ISO15189 accreditation and US laboratories will also seek Clinical Laboratory Improvement Amendments (CLIA) accreditation, allowing them to market LDTs ​​for clinical use. Given the extensive clinical work that has been completed with the Ovarian Cancer Pelvic Mass Triage trial, it is anticipated that this will be ANGLE’s first LDT to be marketed.

ANGLE Founder and Chief Executive, Andrew Newland, comments: “The new clinical service laboratory is an important element in the Company’s commercial strategy and we are pleased to launch a global offering ahead of schedule. This will accelerate the commercialization of the Parsortix system and act as a demonstrator to support product implementation. As well as working with pharmaceutical company customers directly, we would like to work with contract research organizations as both a white label service and, when they wish to implement the test internally, by supplying the Parsortix system so they can immediately offer their own CTC services for cancer drug trials This will allow us to measure the commercial use of the Parsortix system in this large market. We are in follow-up discussions with potential customers and we look forward to renewing the market on the first contract in due time. “

For more information on ANGLE:

ANGLE plc

+44 (0) 1483 343434

Andrew Newland, Chief Executive

Ian Griffiths, Director of Finance

Andrew Holder, Head of Investor Relations

finnCap Ltd (NOMAD and Joint Brokerage)

Corporate Finance – Carl Holmes, Simon Hicks, Teddy Whiley

ECM – Alice Lane, Sunila de Silva

+44 (0) 20 7220 0500

WG Partners (Joint Brokers)

Nigel Barnes, Nigel Birks, Andrew Craig, Chris Lee

+44 (0) 203 705 9330

FTI Consultation

Simon Conway, Ciara Martin

Matthew Ventimiglia (USA)

+44 (0) 203 727 1000

+1 (212) 850 5624

Information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2015.

For Frequently Used Terms, please see the Company’s website at https://angleplc.com/investor-relations/glossary/

About ANGLE plc
CORNER is the world’s leading fluid biopsy company with sample-to-answer solutions. ANGLE’s patent-protected platform includes circulating tumor cell (CTC) harvesting technology and a downstream analysis system for highly multiplex and cost-effective protein and nucleic acid analysis.

The ANGLE cell separation technology is called Parsortix® system, and allows a liquid biopsy (simple blood test) to be used to provide the user with the desired cells in a format suitable for various types of downstream analysis. The system is based on a microfluidic device that captures cells based on their combination of size and compressibility. The system is epitope independent and can capture all types of CTC as well as cluster CTCs in viable (live) form. CTCs allow a complete picture of a cancer to be viewed as an intact cell. CTC allows analysis of DNA, RNA and protein and thus provides an analysis comparable to a tissue biopsy. Since CTC analysis is a noninvasive process, unlike a tissue biopsy, this analysis can be repeated as often as necessary. This is important because cancer develops and changes over time and there is a clear medical need for up-to-date information about its status. Additionally, live-harvested CTCs can be cultivated, which offers the potential for testing response to drugs outside the patient.

Parsortix technology is the subject of 26 patents granted in Europe, United States, China, Australia, Canada, India, Japan and Mexico with three broad patent groups being developed around the world.

The Parsortix system has the CE Mark in Europe for indicated use and, in the United States, a De Novo Filing has been made to the FDA for Parsortix® The PC1 system seeks FDA Classification Class II clearance for use with metastatic breast cancer patients. FDA clearance is seen as a global standard. ANGLE seeks to be the first FDA-approved system to harvest CTC for further analysis.

ANGLE has also completed two separate 200-subject clinical studies under a program designed to develop the ovarian cancer pelvic mass triage test, with results showing a best-in-class accuracy (AUC-ROC) of 95.1%. The pelvic mass triage trial has undergone further refinement and optimization and is currently in the process of a clinical verification study of 200 patients.

ANGLE’s technology for the evaluation of multiplex proteins and nucleic acids of all types is called HyCEADTM Ziplex® platform and is based on a patented flow through array technology. It provides low cost, highly multiplex, fast and sensitive target capture of a wide variety of sample types. The proprietary chemistry approach (the HyCEAD method) allows the capture and amplification of more than 100 biomarkers simultaneously in a single reaction. The HyCEAD Ziplex system is highly sensitive and ideal for measuring the expression of genes and other markers directly from the Parsortix harvest and used in the ovarian cancer pelvic mass triage test to achieve a best-in-class accuracy (AUC-ROC) of 95.1%.

ANGLE’s proprietary technologies can be combined to provide automated sample-to-answer results in centralized laboratories and use-site cartridge formats.

ANGLE has established formal collaborations with world-class cancer centers and major companies such as Abbott, Philips and QIAGEN, and works closely with leading CTC’s translational research customers. These Lead Opinion Leaders (KOLs) work to identify applications with medical utility (clear benefit to patients), and to secure clinical data demonstrating that usefulness in patient studies. Evidence on the benefits of the Parsortix system is growing rapidly from our own clinical studies on metastatic breast cancer and ovarian cancer and also from KOL with 41 peer-reviewed publications and many publicly available posters, available on our website.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as the Primary Information Provider in the UK. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

SOURCE: ANGLE plc

Check out the source version on accesswire.com:
https://www.accesswire.com/638019/ANGLE-PLC-Announces-Global-Launch-of-Clinical-Services-Laboratories

.



image source

The CM House will be under siege if anti-Karachi policies continue, JI warned | Instant News


After showing its strength on Sunday by holding a major march that ended at the Governor’s Building, Jamaat-e-Islami (JI) now plans to put political pressure on the Sindh government led by the Pakistan People’s Party through its 17-point declaration for Karachi’s development.

JI Emir Karachi Hafiz Naeemur Rehman said the party would urge Karachi residents to besiege the Sindh Main Minister’s House after Eid, if the government continues its anti-Karachi policy. “If needed, we can make calls in the holy month of Ramadan.”

JI late Sunday issued a 17-point declaration, demanding that the federal and provincial governments allocate 15 percent of revenue collected from the city for its construction, conduct another census on the city, and allocate Karachi representatives in the appropriate legislative bodies. .

The declaration also demands that the government reconsider the number and limits of union councils in cities based on original figures and put a resourceful and resourceful system of local government with direct elections of mayors. Karachi is declared a mega-metropolitan city and all related institutions are placed under its authority, the JI declaration demands.

The Party is demanding that those at the top of the leadership replace the quota system with one that is truly merit-based with respect to admissions to professional institutions as well as jobs. It also calls for action against the recruitment of false documents, especially domiciles. JI also demanded that the federal and provincial governments jointly ensure the completion of the K-IV water project which began in 2007 within one year and immediately complete the S-III drainage project.

Another point in the declaration is about ending the electricity distribution monopoly in the city along with a forensic audit of the K-Electric account. JI also demands that the government retain at least 51 percent of the company’s shares, ensure the elimination of gas and power cuts, and build a proper mass transit system and the Malir Toll Road. The party is also demanding the full restoration of Pakistan Steel Mill and Pakistan International Airlines.

Referring to the fact that the city generates huge revenue for the country, JI is calling for relaxation for the Karachi business community, especially those affected by the Covid-19 pandemic.

.



image source

The PDM struggle continued until the overthrow of the PTI government: Shahid Khaqan | Instant News


TAXILA: Former prime minister and PML-N center leader Shahid Khaqan Abbasi on Sunday said the struggle for the Pakistan Democratic Movement (PDM) would continue until the PTI government left. Speaking to the media in Taxila at the wedding ceremony of Arshad Abbasi’s son on Sunday, he said the PDM would now rest only after repatriating the incumbent government. The PML-N leadership said that people who understand the causes and are determined to make the effort, will not create the situation on the little things. He said that the PDM would be successful because the people would support it.

Shahid Khaqan Abbasi argues that the excitement in the government camp about developments in the PDM ranks is misplaced as it has the capacity to cope with its complexities through its own mechanisms. He said the PDM party chairman’s meeting would be scheduled for next week and until then informal consultations from the leaders would continue to resolve national issues. He said the PDM struggle had entered a decisive phase and the fear in Prime Minister Imran Khan and his spokesman was clear.

Abbasi said the sitting rulers had destroyed the country economically, socially and politically and the situation demanded the start of a decisive struggle against the ruling regime. The illegal and incompetent dissolution of the PTI government is the voice of every Pakistani, he added.

He said the PTI government had failed miserably on all fronts, and the government’s economic affairs were run by IMF and World Bank people.

Meanwhile, dozens of PML-N administrators and workers staged a demonstration on Sunday in Taxila Chowk against rising prices.

Led by Division President and former Punjab Assembly member Umer Farooq, former National Assembly candidate Ageel Malik led the demonstration as they marched through GT Road. They launched slogans against the government because they could not control price increases.

The participants carried placards and banners reading the slogan: Lower the price of basic food, let the poor live. They say the government has failed to fulfill the promises they made to the people during the election campaign.

Greeting the participants, Umer Farooq said that the prices of daily necessities such as flour, sugar, nuts, vegetables, sugar and petroleum had gone out of people’s purchasing power. He said that people who previously had to fight for bags of flour weighing 10 kg in long lines, now have difficulty getting even 1 kg of sugar.

Attorney Ageel Malik, speaking on the occasion, said those who created starch shortages and raised sugar prices were all sitting in the corridors of the power plant.

He said that instead of giving help to the poor, more and more benefits were provided to the elite class.

.



image source